Clomiphene (Clomid) vs Thyroid (Levothyroxine / Liothyronine T3/T4)

Mechanism

Clomiphene citrate is a racemic mixture of enclomiphene (trans-isomer, estrogen antagonist) and zuclomiphene (cis-isomer, weak estrogen agonist) that acts as a selective estrogen receptor modulator (SERM). It competitively occupies hypothalamic estrogen receptors, blocking the negative feedback of estradiol on GnRH pulse frequency. This disinhibition increases pulsatile GnRH release, stimulating anterior pituitary gonadotrope secretion of both LH and FSH, which in turn drives testicular testosterone synthesis and spermatogenesis. The zuclomiphene isomer has a much longer half-life (~30 days vs. ~10 days for enclomiphene), leading to tissue accumulation with chronic use.

Standard Dosing

Research indicates 25-50 mg daily or every other day for PCT/HPTA restart protocols. Clinical hypogonadism treatment: 25-50 mg daily.

Timing

Take at the same time daily. Evening dosing may reduce perception of visual side effects. No food timing requirements.

Cycle Duration

PCT protocols: 4-8 weeks. Long-term SERM monotherapy: 3-12 months with periodic reassessment. Zuclomiphene accumulation is a concern beyond 6 months.

Side Effects

• Visual disturbances (blurred vision, floaters, light sensitivity — due to zuclomiphene accumulation)
• Mood swings and emotional lability
• Headache
• Nausea
• Hot flashes
• Gynecomastia (paradoxical, from zuclomiphene's estrogenic activity)
• Elevated estradiol (zuclomiphene accumulation)

Contraindications

• Active liver disease or hepatic dysfunction
• Undiagnosed abnormal uterine bleeding (if prescribed to females)
• Ovarian cysts (females)
• Known hypersensitivity to clomiphene
• Pituitary tumor
• Primary hypogonadism (testicular failure — clomiphene only works in secondary hypogonadism)

Best Stacking Partners

Mechanism

Levothyroxine (T4) is a prohormone converted to the active triiodothyronine (T3) by type 1 and type 2 deiodinase enzymes (DIO1/DIO2) in peripheral tissues. T3 binds nuclear thyroid hormone receptors (TRa and TRb), forming heterodimers with retinoid X receptors (RXR) that bind thyroid response elements (TREs) in DNA, directly modulating transcription of genes controlling basal metabolic rate, thermogenesis, mitochondrial biogenesis (via PGC-1a), cardiac output, and neuronal development. T3 also exerts rapid non-genomic effects on mitochondrial respiration, ion channels, and cell membrane transport.

Standard Dosing

Research indicates Levothyroxine (T4): 25-200 mcg daily based on TSH and free T4 levels. Liothyronine (T3): 5-25 mcg daily, often split into 2-3 doses. Combination T4/T3 ratio typically 4:1 to 3:1 when using both.

Timing

Levothyroxine: Take on empty stomach, 30-60 minutes before breakfast or at bedtime (3+ hours after last meal). Separate from calcium, iron, and antacids by 4 hours. Liothyronine: Split into 2-3 daily doses due to short half-life (2.5 hours for T3 vs. 6-7 days for T4).

Cycle Duration

Ongoing for diagnosed hypothyroidism. Optimization protocols may be shorter-term (3-6 months) with reassessment.

Side Effects

• Tachycardia and palpitations (overdose or too-rapid titration)
• Anxiety and insomnia (particularly with T3)
• Tremor
• Weight loss (excessive dosing)
• Hair loss (temporary during initiation or dose changes)
• Heat intolerance and sweating
• Bone density loss at suppressive doses (TSH <0.1)

Contraindications

• Untreated adrenal insufficiency (correct cortisol before thyroid replacement)
• Acute myocardial infarction
• Thyrotoxicosis
• Known hypersensitivity to levothyroxine or liothyronine

Best Stacking Partners